SLC10A3 knockdown inhibited GBM cell proliferation, migration, and invasion, induced cell cycle arrest and apoptosis, reduced M2 macrophage migration, and suppressed xenograft tumor growth.<h4>Discussion</h4>SLC10A3 may promote GBM aggressiveness and immune evasion by regulating malignant phenotypes and macrophage-associated immunosuppression, suggesting its potential as a therapeutic target for GBM. The gene discussed is SLC10A3; the disease is glioblastoma.